BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease
- PMID: 17280537
- DOI: 10.1586/17434440.3.6.731
BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease
Abstract
Drug-eluting stent technology consisting of a bare metal stent, carrier coating, bioactive drug and delivery system, offers an almost infinite range of possible device configurations. A growing understanding of the mechanisms of restenosis allows for the design of synergistic functions within these components, thus providing a basis for new and improved products. The BioMatrix stent (Biosensors Interventional Technologies Pte Ltd., Singapore) elutes the new sirolimus derivative Biolimus A9 from a biodegradable polylactic acid polymer. Biolimus A9 possesses enhanced anti-inflammatory and antiproliferative activity with an improved pharmacokinetic profile. Permanent polymer-carrier-based platforms may be associated with inflammation, late thrombosis and restenosis. The BioMatrix, with its asymmetric and abluminal coating, releases Biolimus A9 into the vessel wall while the polylactic acid polymer is resorbed by surrounding tissues. Clinical studies have demonstrated the BioMatrix to be well tolerated and effective, and it has now become the subject of an aggressive clinical program.
Similar articles
-
Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model.Circ Cardiovasc Interv. 2010 Apr;3(2):174-83. doi: 10.1161/CIRCINTERVENTIONS.109.877522. Circ Cardiovasc Interv. 2010. PMID: 20407114
-
The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study.Eur J Clin Pharmacol. 2011 Apr;67(4):389-398. doi: 10.1007/s00228-010-0895-1. Epub 2010 Oct 9. Eur J Clin Pharmacol. 2011. PMID: 20963405 Clinical Trial.
-
Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.Herz. 2004 Mar;29(2):162-6. doi: 10.1007/s00059-004-2556-6. Herz. 2004. PMID: 15054588 Review.
-
Drug-eluting stents.Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Arch Cardiol Mex. 2006. PMID: 17091802 Review.
-
Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects.Cardiovasc Interv Ther. 2012 Jan;27(1):24-30. doi: 10.1007/s12928-011-0086-8. Epub 2011 Dec 7. Cardiovasc Interv Ther. 2012. PMID: 24122637 Clinical Trial.
Cited by
-
Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model.Korean Circ J. 2013 Nov;43(11):744-51. doi: 10.4070/kcj.2013.43.11.744. Epub 2013 Nov 30. Korean Circ J. 2013. PMID: 24363750 Free PMC article.
-
Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study).Yonsei Med J. 2018 Jan;59(1):72-79. doi: 10.3349/ymj.2018.59.1.72. Yonsei Med J. 2018. PMID: 29214779 Free PMC article.
-
Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3506-14. doi: 10.1016/j.jchromb.2009.08.020. Epub 2009 Aug 21. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19762292 Free PMC article.
-
A First-in-Man Clinical Evaluation of Sirolimus and Ascorbic Acid-Eluting Stent Systems: a Multicenter, Subject-Blinded, Randomized Study.Korean Circ J. 2021 Dec;51(12):1001-1014. doi: 10.4070/kcj.2021.0161. Korean Circ J. 2021. PMID: 34854580 Free PMC article.
-
Safety and Efficacy of Biodegradable Polymer-biolimus-eluting Stents (BP-BES) Compared with Durable Polymer-everolimus-eluting Stents (DP-EES) in Patients Undergoing Complex Percutaneous Coronary Intervention.Korean Circ J. 2019 Jan;49(1):69-80. doi: 10.4070/kcj.2018.0097. Epub 2018 Aug 24. Korean Circ J. 2019. PMID: 30468035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical